Clinical Trial Search

Primary: Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation…

Primary: Percentage Change From Baseline (Week 0) to Week 104 in Body Weight — -15.9; -1.9; -17.3; -2.0 percentage change — p=<.0001

Primary: Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint — 54; 60 Percentage of subjects with TI-AIA

Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations — 11.8; 10.8; 10.3; 11.7 ETDRS Letters — p=0.1718

Primary: Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations — 10.7; 11.6; 10.9; 10.6 ETDRS Letters — p=0.4699

Primary: Change in Body Weight (%) — -9.9; -13.4; -1.9 Percentage change — p=<.0001

Primary: Maintenance of Wakefulness Test (MWT) — 10.8; 4.7 minutes — p=<0.001

Primary: Change in Hemoglobin From Baseline to Day 35 — 0.70 g/dL — p=0.1711

Primary: Mean Change in Low Shear Blood Viscosity — 1.045; -1.793; -1.759 5 s^-1 cPs

Primary: Number of Participants With New Heart Failure Hospitalization — 240; 259; 244; 255 Participants

Primary: Peak Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Within 4 Hours Post-dose Following 1 Week of Treatment — 0.256; 0.274 L — p=0.3450

Primary: Relapse-free Survival — 38; 60; 13; 32 participants

Primary: Percentage of Patients With Occurrence of Severe Bleeding and/or Liver Failure — 5.88; 2.78 percentage of participants

Primary: Change in Pupil Diameter From Baseline — 4.747; 4.779; 0.134; 0.032 millimeters

Primary: Change in Pupil Diameter From Baseline — 2.672; 2.583; 2.657; 2.569 millimeters